Breakout Bulletin: June 7-12

You’re busy. Between patients, prior authorizations, inbox messages, and everything else on your plate, keeping up with the literature is the first thing that slips. Dermatology Times NP/PA Connect is here to make sure it doesn’t. Each week, we pull the most clinically relevant news from across dermatology and bring it straight to your inbox — what’s new, what it means, and what’s worth watching. This week: a CAR T therapy showing durable remission in dermatomyositis without ongoing immunosuppression, a rare BCC syndrome finally getting a registrational trial, the first IND ever filed for peeling skin syndrome, new practice guidance on a frequently missed manifestation of psoriasis, and an early-phase AD topical worth watching — with some caveats.

Lebrikizumab Can Now Be Dosed Every 8 Weeks — Six Injections a Year

The FDA has approved an every-8-week maintenance dosing regimen for lebrikizumab (Ebglyss; Eli Lilly) in adults and adolescents 12 and older with moderate to severe atopic dermatitis, adding a new option to a label that previously offered monthly maintenance dosing only. Eligible patients who achieve adequate response during induction can now maintain disease control with as few as 6 injections per year.¹

The approval was supported by longitudinal exposure-response modeling and clinical data from the every-8-week extension of the phase 3 ADjoin (NCT04392154) long-term study, which enrolled patients from the ADvocate 1 (NCT04146363) and 2 (NCT04178967) trials, the ADore adolescent (NCT04250350) study, and the ADopt-VA (NCT04626297) study. The 32-week extension evaluated both every-4-week and every-8-week maintenance dosing regardless of prior schedule or response status at entry. No new safety signals emerged, and no patients discontinued due to adverse events. The most common adverse reactions were conjunctivitis, injection-site reactions, and herpes zoster — consistent with the established profile.

MORE ON AD

The approved dosing sequence: 500 mg loading dose (2 250 mg injections) at weeks 0 and 2, then 250 mg every 2 weeks through week 16 or until adequate response, followed by maintenance at either every-4-week or every-8-week intervals.

“Every 8 weeks maintenance dosing for lebrikizumab is a significant differentiator among IL-13 and IL-4R targeted biologics and must be considered in shared clinical decision making.”— Christopher G. Bunick, MD, PhD, Yale School of Medicine / Editor in Chief, Dermatology Times

▶ Why it matters: When a patient’s skin is clear and itch is controlled, 6 injections a year versus 12 is a real quality-of-life difference. This approval gives you a concrete option to offer when patients ask about reducing their treatment burden.

An Oral Psoriasis Drug Just Beat the Only Approved TYK2 Inhibitor Head-to-Head

Zasocitinib (TAK-279; Takeda) achieved statistically significant superiority over deucravacitinib across all primary and key secondary endpoints in the LATITUDE Atlas phase 3 head-to-head trial, with more than 35% of zasocitinib-treated patients reaching complete skin clearance (PASI 100) at week 16 compared with approximately 14% on deucravacitinib — a more than 2.5-fold difference.²

PASI 90 and sPGA 0 at week 16 also favored zasocitinib with statistical significance, and separation between treatment arms emerged as early as week 8. The broader LATITUDE phase 3 program against placebo and apremilast showed approximately 70% of patients achieving clear or nearly clear skin at week 16, with PASI 90 exceeding 60% in some cohorts and over 90% of patients maintaining that response through week 60. Quality-of-life gains followed: up to 60% of patients achieved DLQI 0 or 1 by week 24, indicating no meaningful impact of psoriasis on daily life.

MORE ON PSORIASIS

Zasocitinib achieves more than 1-million-fold selectivity for TYK2 over other JAK family members, targeting the IL-23/IL-17 axis and type I interferon signaling while sparing the broader biological processes — including lipid metabolism and hematopoiesis — regulated by JAK1, JAK2, and JAK3. Safety was consistent with the TYK2 class: no new signals, no cardiovascular events, no tuberculosis reactivation. Takeda is on track to submit an NDA within this fiscal year.

“Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies. These findings show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance.”— Melinda Gooderham, MD, commenting on the LATITUDE data

▶ Why it matters: Deucravacitinib has been the only approved oral TYK2 inhibitor in psoriasis. Zasocitinib is now headed toward NDA submission with head-to-head superiority data against it. When this drug reaches your patients, the oral psoriasis conversation will have a meaningfully higher efficacy ceiling to offer.

Sunscreen Just Got Its First New Active Ingredient in Nearly 30 Years

The FDA has approved bemotrizinol as a permitted active ingredient in OTC sunscreen products — the first addition to the sunscreen monograph since the late 1990s and the first ingredient approved through the streamlined CARES Act administrative order process. The ingredient is approved for use in adults and children 6 months and older at concentrations up to 6%.³

Bemotrizinol provides broad-spectrum UV-A and UV-B protection, has low skin absorption, and rarely causes skin irritation, based on FDA’s review of available data. The ingredient has been used in European and other international sunscreen formulations for years before this US action. For patients — and NPs and PAs who counsel them — its significance is largely cosmetic: bemotrizinol allows for more aesthetically elegant formulations that are easier to apply and less likely to leave a white cast, which is one of the most commonly cited barriers to consistent sunscreen use.

“This approval gives experts in formulation elevated ingredients to work with. At the end of the day, the best sunscreen is the one you will use, and the approval of this filter makes the options that much better for our patients.”— Kavita Mariwalla, MD, FAAD, American Society for Dermatologic Surgery

▶ Why it matters: Adherence is the whole game in photoprotection. When patients ask why European sunscreens feel better, you now have a specific answer — and a regulatory development that means US-formulated products are about to improve.

A Rare Blistering Disease Moves Closer to Approved Therapy in Canada

Health Canada has accepted a New Drug Submission for birch triterpenes topical gel (Filsuvez; Chiesi Global Rare Diseases) for priority review, proposing its use in the treatment of wounds associated with dystrophic and junctional epidermolysis bullosa in patients 6 months and older. Priority review in Canada is granted to therapies for serious or life-threatening conditions with limited or no comparable treatment options; the accelerated review timeline is approximately 180 days.

The submission is supported by data from EASE, the pivotal phase 3 trial published in the British Journal of Dermatology, along with a 24-month open-label follow-up. Birch triterpenes topical gel has already received FDA approval (2023) and European Commission approval (2022) for wounds associated with dystrophic and junctional EB, and was most recently registered in Australia in May 2026.1 Canadian regulatory clearance would extend access to a patient population managing one of dermatology’s most burdensome rare conditions — characterized by extreme skin fragility, chronic wounds, elevated squamous cell carcinoma risk, and multisystem complications.

▶ Why it matters: For APPs in centers with EB programs or rare genodermatosis referrals, this regulatory milestone means Canadian patients are moving toward the same approved option available in the US and Europe. The global regulatory convergence for this drug is worth noting.

References

1. FDA approves Lilly's EBGLYSS® (lebrikizumab-lbkz) for one maintenance dose every eight weeks in patients with moderate-to-severe atopic dermatitis. News release. Eli Lilly and Company. Published June 9, 2026. Accessed June 11, 2026. https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-ebglyssr-lebrikizumab-lbkz-one-maintenance
2. Takeda’s zasocitinib significantly outperforms deucravacitinib in head-to-head phase 3 psoriasis study, promising to redefine oral treatment expectations. News release. Takada. Published June 11, 2026. Accessed June 11, 2026. https://www.takeda.com/newsroom/newsreleases/2026/zasocitinib-outperforms-deucravacitinib-study/
3. FDA expands sunscreen options for the first time in 20 years. News release. FDA. June 9, 2026. Accessed June 11, 2026. https://www.fda.gov/news-events/press-announcements/fda-expands-sunscreen-options-first-time-20-years
4. Chiesi Global rare diseases announces Health Canada grants priority review for FILSUVEZ® (birch triterpenes) topical gel for the treatment of epidermolysis bullosa. News release. Chiesi Global Rare Diseases. Published June 9, 2026. Accessed June 11, 2026. https://www.globenewswire.com/news-release/2026/06/09/3308760/0/en/chiesi-global-rare-diseases-announces-health-canada-grants-priority-review-for-filsuvez-birch-triterpenes-topical-gel-for-the-treatment-of-epidermolysis-bullosa.html?_gl=1*kt0edv*_up*MQ..*_ga*MTkyODU1ODE3NC4xNzgxMDA5OTcz*_ga_B6167QB2TF*czE3ODEwMDk5NzMkbzEkZzAkdDE3ODEwMDk5NzMkajYwJGwwJGgyMTI3OTI4NTY5*_ga_ERWPGTJ5X8*czE3ODEwMDk5NzMkbzEkZzAkdDE3ODEwMDk5NzMkajYwJGwwJGgw